Market Overview

Melanoma Research Alliance Announces New Funding Opportunity for Research to Accelerate Progress Toward Curing Melanoma


$9 Million in Funding for Melanoma Research including Special
Opportunities in Artificial Intelligence, Dermatology, Immunotherapy &
Radiation Oncology

The Melanoma Research Alliance (MRA), the largest non-profit funder of
melanoma research worldwide, is pleased to announce its 2018 – 2019
Request for Proposals for preclinical, translational and early clinical
research with the power to transform melanoma prevention, detection,
staging and treatment.

This funding cycle, the RFP includes special opportunities in several
areas including dermatology as well as artificial intelligence applied
to melanoma. In addition, MRA is partnering with ASTRO (the American
Society for Radiation Oncology) to offer an award for radiation-oncology
melanoma research and is pleased to have support from Bristol-Myers
Squibb for two immunotherapy-focused young investigator awards.

"Melanoma research has been at the leading edge of oncology research,
and our special opportunity focus areas, such as artificial intelligence
and immunotherapy, reflect this," said MRA Scientific Program Director
Kristen Mueller, Ph.D. "We are excited to continue to offer
opportunities to fund high-impact research that will help eliminate
suffering and death due to melanoma."

MRA's annual RFP is shaped by staff,
Board and expert scientific advisors
who help determine the emphasis
areas and special opportunities where MRA can leverage its role to spur
and sustain innovation and the pace of progress.

"Another special opportunity focus area for this year's RFP is
dermatologist-led research," MRA President & CEO Michael Kaplan. "We are
thrilled to support this research, especially since, for many people
with melanoma, the dermatologist office is where their journey begins."

The 2018 - 2019 award cycle will support at least $9 million in funding.
Information including eligibility criteria, award types, and deadlines
can be found on the MRA website at:

The Melanoma Research Alliance is on the forefront of accelerating
research and saving the lives of people afflicted with melanoma, the
deadliest skin cancer. Over the past 10 years, MRA has invested $101
million—and leveraged an additional $101 million—to support 266 research
projects across 15 countries. MRA-funded research has studied 96 unique
therapeutic approaches including 11 of the 12 new treatment options
approved by the FDA since 2011.

About Melanoma Research Alliance (MRA)

Founded in 2007 under the auspices of the Milken Institute, with the
generous support of Debra and Leon Black, the Melanoma Research Alliance
exists to accelerate treatment options and find a cure for melanoma. As
the largest nonprofit funder of melanoma research, it has dedicated over
$101 million and leveraged an additional $101 million towards its
mission. Through its support, MRA has championed revolutions in
immunotherapy, targeted therapies, novel combinations and diagnostics.
Due to the ongoing support of its founders, 100 percent of donations to
MRA go directly to its melanoma research program. MRA's ability to fund
wide-ranging research in melanoma is amplified by unique collaborations
and partnerships with individuals, private foundations, and
corporations. Visit
for more information.

View Comments and Join the Discussion!